A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501684-40-00

Acronym

GS-US-570-6015

Enrollment

Registered

2023-07-06

Start date

2023-10-05

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric and Esophagogastric Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Microsatellite Stable Metastatic Colorectal Cancer, Non-Small-Cell Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Belgium, Spain

Outcome results